These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12851475)

  • 1. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
    D'Andrea AD
    Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
    Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
    Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
    de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
    Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
    Wang Z; Li M; Lu S; Zhang Y; Wang H
    Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER; Ricker JL; Chen Z; Waes CV
    Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FANCF methylation contributes to chemoselectivity in ovarian cancer.
    Olopade OI; Wei M
    Cancer Cell; 2003 May; 3(5):417-20. PubMed ID: 12781358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
    He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
    Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
    Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
    Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
    Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
    J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
    Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
    Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
    Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
    Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway.
    Medhurst AL; Huber PA; Waisfisz Q; de Winter JP; Mathew CG
    Hum Mol Genet; 2001 Feb; 10(4):423-9. PubMed ID: 11157805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
    Yamashita T; Nakahata T
    Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
    Xie J; Kim H; Moreau LA; Puhalla S; Garber J; Al Abo M; Takeda S; D'Andrea AD
    J Clin Invest; 2015 Apr; 125(4):1523-32. PubMed ID: 25751062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis of fanconi anemia.
    Taniguchi T; Dandrea AD
    Int J Hematol; 2002 Feb; 75(2):123-8. PubMed ID: 11939257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and the sensitive cell.
    Bagby GC; Olson SB
    Nat Med; 2003 May; 9(5):513-4. PubMed ID: 12724761
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
    Burkitt K; Ljungman M
    Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Boolean network model of the FA/BRCA pathway.
    Rodríguez A; Sosa D; Torres L; Molina B; Frías S; Mendoza L
    Bioinformatics; 2012 Mar; 28(6):858-66. PubMed ID: 22267503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the Fanconi anemia pathway by monoubiquitination.
    Gregory RC; Taniguchi T; D'Andrea AD
    Semin Cancer Biol; 2003 Feb; 13(1):77-82. PubMed ID: 12507559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.